

GenCore version 4.5 Copyright (c) 1993 - 2000 Compugen Ltd.		Search results for query: "nucleic search, using sw model"									
Line	Text	Score	Query	Match	Length	DB	ID	Description	Location/Qualifiers		
1	1 nucleic - nucleic search, using sw model										
2	on:										
3	January 3 , 2002, 20:10:34 ; Search time 271.41 Seconds (without alignments)										
4	16052.934 Million cell updates/sec										
5	title: US-09-497-822A-18										
6	perfect score: 5082										
7	sequence: 1 gagctcgacaaattggag.....acaagcaacaaaaaaa 5082										
8	oring table: IDENTITY NUC Gapext 1.0										
9	total number of hits satisfying chosen parameters: 930621 seqs, 428662619 residues										
10	nimum DB seq length: 0										
11	ximum DB seq length: 2000000000										
12	st-processing: Minimum Match 0%										
13	Listing first 45 summaries										
14	atabase : N_Geneseq_1101:*										
15	1: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1980.DAT:*										
16	2: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1981.DAT:*										
17	3: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1982.DAT:*										
18	4: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1983.DAT:*										
19	5: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1984.DAT:*										
20	6: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1985.DAT:*										
21	7: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1986.DAT:*										
22	8: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1987.DAT:*										
23	9: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1988.DAT:*										
24	10: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1989.DAT:*										
25	11: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1990.DAT:*										
26	12: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1991.DAT:*										
27	13: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1992.DAT:*										
28	14: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1993.DAT:*										
29	15: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1994.DAT:*										
30	16: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1995.DAT:*										
31	17: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1996.DAT:*										
32	18: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1997.DAT:*										
33	19: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1998.DAT:*										
34	20: /SIDS2/gcdata/geneseq/geneseq/geneseq/NA1999.DAT:*										
35	21: /SIDS2/gcdata/geneseq/geneseq/NA2000.DAT:*										
36	22: /SIDS2/gcdata/geneseq/geneseq/NA2001.DAT:*										
37	Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the total score distribution, and is derived by analysis of the total score distribution.										
38	SUMMARIES										
39	result 1										
40	ID AAZ23424 standard; DNA; 3715 BP.										
41	ID AAZ23424 standard; DNA; 3715 BP.										
42	XX										
43	XX										
44	XX										
45	XX										
46	DT 19-JAN-2000 (first entry)										
47	XX										
48	DE Human androgen receptor DNA.										
49	XX										
50	KW Proapoptotic; dependence domain; P75NTR; androgen receptor; DCC; huntingtin polypeptide; Machado-Joseph disease; SCAL; SCA2; SCA6; atrophin-1; cell death; apoptosis; Huntington's disease; head trauma; Alzheimer's disease; Kennedy's disease; spinocerebellar ataxia; stroke; dentatorubropallidoluysian atrophy; cell proliferation; cell survival; neoplastic; malignant; autoimmune; fibrotic; ss.										
51	XX										
52	OS Homo sapiens.										
53	XX										
54	FH Key CDS										
55	FT FT										
56	FT FT										
57	XX										
58	XX										
59	XX										
60	XX										
61	XX										
62	XX										
63	XX										
64	XX										
65	XX										
66	XX										
67	XX										
68	XX										
69	XX										
70	XX										
71	XX										
72	XX										
73	XX										
74	XX										
75	XX										
76	XX										
77	XX										
78	XX										
79	XX										
80	XX										
81	XX										
82	XX										
83	XX										
84	XX										
85	XX										
86	XX										
87	XX										
88	XX										
89	XX										
90	XX										
91	XX										
92	XX										
93	XX										
94	XX										
95	XX										
96	XX										
97	XX										
98	XX										
99	XX										
100	XX										
101	XX										
102	XX										
103	XX										
104	XX										
105	XX										
106	XX										
107	XX										
108	XX										
109	XX										
110	XX										
111	XX										
112	XX										
113	XX										
114	XX										
115	XX										
116	XX										
117	XX										
118	XX										
119	XX										
120	XX										
121	XX										
122	XX										
123	XX										
124	XX										
125	XX										
126	XX										
127	XX										
128	XX										
129	XX										
130	XX										
131	XX										
132	XX										
133	XX										
134	XX										
135	XX										
136	XX										
137	XX										
138	XX										
139	XX										
140	XX										
141	XX										
142	XX										
143	XX										
144	XX										
145	XX										
146	XX										
147	XX										
148	XX										
149	XX										
150	XX										
151	XX										
152	XX										
153	XX										
154	XX										
155	XX										
156	XX										
157	XX										
158	XX										
159	XX										
160	XX										
161	XX										
162	XX										
163	XX										
164	XX										
165	XX										
166	XX										
167	XX										
168	XX										
169	XX										
170	XX										
171	XX										
172	XX										
173	XX										
174	XX										
175	XX										
176	XX										
177	XX										
178	XX										
179	XX										
180	XX										
181	XX										
182	XX										
183	XX										
184	XX										
185	XX										
186	XX										
187	XX										
188	XX										
189	XX				</						

Bredesen DE, Rabizadeh S;
 XX
 WPI; 1990-561617/47.
 DR
 P-PSDB: AAY33491.
 XX
 New proapoptotic peptides, used to develop products for
 PT
 treating, e.g., Alzheimer's disease.
 Disclosure; Page 86-90; 1990pp; English.
 PS
 PS
 XX
 This invention describes novel pure proapoptotic dependence peptides
 CC which comprise a sequence of an active dependence domain selected from
 CC dependence polypeptides consisting of p75^{TR}R, androgen receptor, DCC,
 CC huntingtin polypeptide, Machado-Joseph disease gene product, SCAl, SCA2,
 CC SC46 and atrophin-1 polypeptide. The proapoptotic peptides are capable
 CC of inducing cell death and can be used to develop products to mediate or
 CC inhibit apoptosis. The methods can be used for reducing the severity of
 CC a proapoptotic dependence domain mediated pathological conditions e.g.,
 CC Huntington's disease, Alzheimer's disease, Kennedy's disease,
 CC spinocerebellar ataxias, dentatorubropallidoluysian atrophy,
 CC stroke or head trauma. They can also be used for
 CC reducing the severity of a pathological condition mediated by upregulated
 CC cell proliferation or cell survival e.g. neoplastic, malignant,
 CC autoimmune or fibrotic conditions. This sequence encodes a human
 CC androgen receptor described in the method of the invention.
 Sequence 3715 RP: 841 A: 1055 C: 1001 G: 818 T: 0 other
 XX

2

AAQ1Z001
ID XXX

